Aclidinium bromide: Phase III data

In each of 2 double-blind, international Phase III trials (ACCLAIM/COPDI and ACCLAIM/COPDII) in 1,647 patients with moderate to severe COPD, 200 ug once-daily aclidinium met the primary endpoint of a ...